AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
3.030
+0.190 (6.69%)
At close: Apr 28, 2026, 4:00 PM EDT
2.931
-0.099 (-3.27%)
After-hours: Apr 28, 2026, 7:33 PM EDT
AC Immune Revenue
In the year 2025, AC Immune had annual revenue of 3.57M CHF, down -86.92%. AC Immune had revenue of 338.00K in the quarter ending December 31, 2025, a decrease of -70.27%.
Revenue (ttm)
3.57M CHF
Revenue Growth
-86.92%
P/S Ratio
66.60
Revenue / Employee
29,287 CHF
Employees
122
Market Cap
300.58M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.57M | -23.74M | -86.92% |
| Dec 31, 2024 | 27.31M | 12.51M | 84.51% |
| Dec 31, 2023 | 14.80M | 10.87M | 276.14% |
| Dec 31, 2022 | 3.94M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 15.43M | -95.03M | -86.03% |
| Dec 31, 2019 | 110.46M | 103.54M | 1,498.03% |
| Dec 31, 2018 | 6.91M | -13.34M | -65.88% |
| Dec 31, 2017 | 20.26M | -2.96M | -12.75% |
| Dec 31, 2016 | 23.21M | -15.88M | -40.61% |
| Dec 31, 2015 | 39.09M | 8.82M | 29.14% |
| Dec 31, 2014 | 30.27M | 21.63M | 250.46% |
| Dec 31, 2013 | 8.64M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 79.59M |
| Editas Medicine | 40.52M |
| Foghorn Therapeutics | 30.91M |
| Zentalis Pharmaceuticals | 26.87M |
| LENZ Therapeutics | 19.09M |
| Abeona Therapeutics | 5.82M |
| Inhibikase Therapeutics | 1.00 |
ACIU News
- 21 days ago - AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly - GlobeNewsWire
- 6 weeks ago - AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 4 months ago - AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - Benzinga
- 4 months ago - AC Immune Transcript: Study Update - Transcripts
- 4 months ago - AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease - GlobeNewsWire
- 5 months ago - AC Immune Transcript: Jefferies London Healthcare Conference 2025 - Transcripts
- 6 months ago - AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 6 months ago - First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine - GlobeNewsWire